Overall, these findings suggest that females with the CHEK2 1100delC GPV and the CHEK2 I157T GPV are provided with similar cancer risk management recommendations, despite the I157T GPV having a breast cancer risk of less than 20%, which does not meet the threshold at which high-risk breast screening is recommended [14,16]. This evidence concerns the gene CHEK2 and breast cancer.